

<small>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</small>	
<u>EV524412099 U.S.</u> Express Mail Label Number	<u>6/16/05</u> Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
BADACHE ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/012295

FILED: 4 NOVEMBER 2003

U.S. APPLICATION NO: 10/533,503

35 USC §371 DATE: 2 MAY 2005

FOR: TEL-ETV6 MEDIATED INHIBITION OF CELL PROLIFERATION

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/012295, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



John T. Prince  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

Date: June 16, 2005